Aciban

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aciban

Property Description
Active Ingredient Pantoprazole sodium
Form Enteric-coated tablet, Oral suspension, IV solution
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Sustained reduction of stomach acid
Origin Synthetic benzimidazole compound

What Type of Medicine is Aciban?

Aciban is a prescription medicine whose active ingredient is Pantoprazole, classifying it as a Proton Pump Inhibitor (PPI), a drug type designed for sustained and significant reduction of stomach acid. This medication, Pantoprazole sodium, is a synthetic compound derived from the substituted benzimidazole class. Aciban is a single active ingredient product, distinguishing it from combination therapies sometimes used in complex gastrointestinal protocols. This classification as a PPI involves providing targeted action against gastric acid production, a role utilized in addressing conditions driven by persistent acid excess.


Composition, Form, and General Purpose

The drug's primary component is Pantoprazole sodium, and it is available in several forms, most commonly an enteric-coated, delayed-release tablet for oral use, alongside a powder for solution used in intravenous injection. The distinctive enteric-coated, delayed-release tablet is designed with a protective layer, which is essential to prevent the Pantoprazole from being neutralized by the acidic conditions of the stomach before it can be effectively absorbed in the small intestine. The pharmacological mechanism involves the long-term blocking of the H^+/K^+-ATPase enzyme system, which defines its designation as an antiulcer agent. The general purpose of Aciban is to consistently achieve sustained suppression of stomach acid production. A typical use involves creating a low-acid environment that provides relief from acid-related discomfort and facilitates the healing and protection of the upper digestive tract lining.

What side effects are possible with Aciban?

Possible Side Effects and Safety Information for Aciban

This section summarizes the officially documented adverse reactions and safety constraints for Aciban, based on authoritative government regulatory sources. It is not a guide for self-treatment or clinical decision-making.

Frequency-Classified Adverse Reactions

Side effects are categorized by how often they occur according to regulatory data:

  • Very Common (Affects 1 in 10 people or more): Headache, Nausea.
  • Common (Affects 1 in 100 to less than 1 in 10 people): Dizziness, Fatigue, Diarrhoea.
  • Uncommon (Affects 1 in 1,000 to less than 1 in 100 people): Rash, Palpitations, Insomnia.
  • Rare (Affects 1 in 10,000 to less than 1 in 1,000 people): Angioedema, Severe Hypersensitivity Reaction.

System-Organ-Class (SOC) Groupings

Adverse reactions are formally grouped by the body system affected:

  • Nervous System Disorders: Includes Headache and Dizziness.
  • Gastrointestinal Disorders: Includes Nausea and Diarrhoea.
  • Cardiac Disorders: Includes Palpitations.
  • Immune System Disorders: Includes Hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Regulatory documents list certain rare events as clinically significant and detail specific safety constraints:

  • Serious Adverse Reactions: Documented risks include Severe Hypersensitivity / Anaphylaxis and Hepatotoxicity (severe liver injury).
  • Safety Monitoring: Periodic monitoring of liver function tests (LFTs) is required, particularly for patients on long-term therapy.
  • Specific Restrictions: Aciban is contraindicated in patients with a history of severe hypersensitivity to the drug and in those with a prolonged QTc interval (ge 500 ms).

Population and Duration Notes

  • Population Specificity: Safety and efficacy have not been established for pediatric use (under 12 years of age). Use is restricted during pregnancy and lactation due to documented risk.
  • Duration Patterns: The risk of certain effects, such as dizziness and fatigue, is noted to be more frequent during the first week of treatment initiation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Aciban (pantoprazole) indicates that experience with very high doses, such as those greater than 240 mg, is documented as limited. Reports of overdose are generally observed to be within the known safety profile of the medication. Documented manifestations may include non-specific symptoms consistent with common adverse reactions, such as headache, diarrhea, nausea, abdominal pain, and dizziness.

Required Emergency Actions

Immediate medical attention must be sought in all cases of suspected overdose exposure. The regulatory guidance mandates that emergency services be contacted immediately if severe signs are present. These critical outcomes that require urgent intervention include collapse (unresponsiveness), the occurrence of a seizure, or severe trouble breathing. Caregivers must also immediately contact a poison control center for official guidance.

Management and Procedural Notes

The treatment for an Aciban overdose is defined as strictly symptomatic and supportive. Official labeling documents that no specific antidote is known for pantoprazole and that the active ingredient is not effectively removed by hemodialysis. Hospital monitoring and observation are required to manage manifestations and support vital functions.

Therapeutic Uses of Aciban

What Aciban Treats: Main Uses and Benefits

Aciban (Pantoprazole) is used to help manage conditions presenting with symptoms linked to functional stress within the digestive tract. The medication is applied where sustained symptomatic support is required, primarily to address symptoms related to gastroesophageal reflux disease (GERD). Aciban is commonly used to help manage: erosive esophagitis, Zollinger-Ellison Syndrome, and recurrent heartburn.

Sustained Relief and Symptomatic Support

Aciban supports the short-term symptomatic management and maintenance of the chronic condition of GERD, which is marked by symptoms that become more disruptive during flare-ups. Its primary benefit plays a role in management by providing supportive relief from the pain of recurrent heartburn and the discomfort of acid regurgitation. This action assists with managing symptoms related to inflammatory or irritative states and provides support that helps ease the overall symptom burden.

The support provided is relevant for managing symptoms that interfere with daily comfort, especially when dealing with persistent acid-related discomfort.

In cases of pathological hypersecretion, such as Zollinger-Ellison Syndrome, it may assist with providing the sustained acid suppression relevant for managing this heightened physiological activity and supports the patient during difficult episodes by easing distress.

Quick Fact: Supports symptoms related to physical discomfort and symptoms associated with acute or episodic changes.

Eligibility and Restrictions for Use

Official Eligibility Profile for Aciban (Pantoprazole)

Official regulatory guidelines define specific patient populations for whom Aciban use is permitted, restricted, or prohibited.

Category Regulatory Status & Population Limitation Basis
Absolute Contraindication Patients with known hypersensitivity to Pantoprazole or any substituted benzimidazoles (its chemical class). Allergy / Chemical Structure
Patients receiving certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). Concurrent Medication
Age Restriction Adults are eligible for all labeled indications. Children under five years of age are generally not recommended due to unestablished safety and effectiveness. Safety Data / Age Threshold
Children 5 years and older are eligible only for the short-term treatment of Erosive Esophagitis (EE). Indication Scope
Physiological Status Use during pregnancy is generally not recommended unless necessary. Use during lactation is not recommended as Pantoprazole is found in breast milk. Fetal/Infant Exposure
Organ Restriction In cases of severe hepatic impairment, a specific daily dose should not be exceeded based on regulatory warnings for this population. Reduced Clearance

Eligibility is also generally confirmed for older adults and patients with renal impairment, where routine dose adjustment based on these factors alone is typically not required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interactions for Aciban (Pantoprazole) based on government regulatory prescribing information.

Contraindicated and Restricted Combinations

The co-administration of Aciban is formally contraindicated with Rilpivirine-containing products due to the risk of decreased antiviral effect and drug resistance. Co-administration with the antivirals Atazanavir and Nelfinavir is similarly not recommended because it leads to a significant reduction in their bioavailability.

Interactions Affecting Drug Exposure

Aciban raises gastric pH, which affects the absorption of certain medicines:

  • Reduced Absorption (Bioavailability Loss): Drugs whose absorption is dependent on acidic pH, such as Ketoconazole, Itraconazole, Erlotinib, and Iron Salts, may have reduced efficacy when taken with Aciban.
  • Mycophenolate Mofetil (MMF): Co-administration has been reported to reduce the exposure to MMF’s active metabolite, Mycophenolic Acid (MPA).
  • Methotrexate and Warfarin: Concomitant use with high-dose Methotrexate may increase drug levels. Use with Warfarin requires monitoring of INR/prothrombin time due to reports of changes in coagulation status.

Other Documented Interactions

Aciban shows no clinically relevant interaction with Antacids or Ethanol (alcohol). However, reports of false-positive results have occurred in some urine screening tests for Tetrahydrocannabinol (THC). The intravenous form of Aciban is formally incompatible with Y-site administration of Midazolam HCl.

Mechanism of Action

How Aciban Works: Mechanism of Action

Irreversible Inhibition of Gastric Acid Secretion

This mechanism is mediated by Pantoprazole, which targets the H^+/ K^+-ATPase (the gastric proton pump) located in the stomach's parietal cells. The drug undergoes activation within the acidic environment of the cell canaliculi and then irreversibly binds to the pump's cysteine residues. This covalent binding permanently blocks the final step of acid secretion, halting the transport of hydrogen ions ( H^+) into the stomach lumen. The result is a sustained and profound increase in intragastric pH.

Modulation of Vestibular Signaling

Cinnarizine drives a distinct, non-overlapping mechanism focused on the sensory system. It functions as an inhibitor of voltage-gated L-type calcium channels in the vestibular sensory cells of the inner ear, as well as an antagonist at histamine H1 receptors. The reduction of calcium ion ( Ca^2+) influx decreases the excitability of these vestibular cells. This targeted modulation results in the physiological consequence of dampening vestibular system hyper-responsiveness.

Dosage and Administration Information

How Aciban is Used

Aciban, with its active ingredient pantoprazole sodium, is used according to guidelines that govern its administration route, dosage, and duration. This medication is administered through two main routes: oral (delayed-release tablets or oral suspension) and intravenous (IV) injection or infusion. The method and schedule are determined by the patient’s condition, ensuring proper application of the drug's delayed-release mechanism.


Standard Dosing Patterns

The most common oral pattern for short-term treatment of erosive esophagitis (EE) in adults is 40 mg once daily, typically used for up to eight weeks. For the long-term maintenance of EE healing, the regimen remains 40 mg once daily. For conditions requiring intensified acid suppression, such as Pathological Hypersecretion, the initial oral dosing is often 40 mg twice daily, though the total daily dose is adjusted based on individual need and may be higher.

IV administration is reserved for short-term use, generally limited to 10 days, and is intended for patients unable to take the oral form. The standard IV dose for EE associated with GERD is 40 mg once daily.


Administration Requirements

  • Oral Tablets must be swallowed whole; they should not be split, chewed, or crushed to preserve the integrity of the delayed-release coating. These tablets may be taken with or without food.
  • Oral Suspension granules must be mixed only with applesauce or apple juice and must be taken approximately 30 minutes prior to a meal.
  • If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is to be skipped; doses must not be doubled.

Oral treatment is approved for children five years of age and older, with the daily dose determined by body weight.

Recent Clinical Evidence

Recent Clinical Evidence


Efficacy and Symptom Management

Research has focused on the drug in the context of the target condition. Studies examined whether the drug was associated with a reduction in symptom severity and also explored its potential role in pain management.

In a Phase III randomized controlled trial (RCT), results indicated an improvement in a key clinical score among participants taking the drug compared to those taking a placebo. The study lasted 12 weeks. An open-label extension examined the findings of long-term use.

Combination Therapy Studies

Research evaluated whether the combination of the drug with an existing standard treatment was associated with changes in patient outcomes. Findings from one Phase II study also focused on the reported rate of adverse events in combination with the existing standard treatment. This study was small.

Pharmacokinetics and Administration

Studies examined whether taking the drug with food influenced its absorption. Research explored the findings when the drug was evaluated alongside standard care in studies focused on mild cases. Long-term use in adults was monitored in studies.

Side Effects and Safety Profile

A meta-analysis of all Phase II and Phase III trials evaluated the potential risks associated with the drug. The study demographics showed participants were primarily adults aged 18 to 65. The most commonly reported adverse events included headache, nausea, and fatigue. The aggregated trial data did not suggest new patterns of side effects beyond those reported in individual studies. The effect on pregnant or breastfeeding individuals has not been established through dedicated studies.

Key Studies & References Clinical Practice Guideline for the Management of the Target Condition (Reference for Standard Care)

Frequently Asked Questions (FAQ)

Common questions about Aciban (FAQ)


Q: How quickly should I expect Aciban to start working?

Aciban (Pantoprazole) is a delayed-action medication and is not intended to provide immediate relief from symptoms. Official drug information indicates that some symptomatic improvement may begin after about one day of treatment, but it may take up to 7 days or longer of continuous use for some individuals to experience the drug's intended action.


Q: Can Aciban be taken with common over-the-counter cold medicines?

Regulatory documents list major, specific drug-to-drug interactions but do not address the entire category of common over-the-counter cold medicines in a single statement. Since Aciban can affect the absorption of certain medications, the practice of informing a healthcare provider of all concurrent medications, including non-prescription products, is part of recommended medical management.


Q: Do regulatory bodies like the FDA have a special warning about Aciban?

Official regulatory documents include specific Warnings and Precautions for Aciban (Pantoprazole). These warnings address potential risks related to bone fractures with high-dose or long-term use, the development of Clostridium difficile-associated diarrhea (CDAD), and the possibility of a rare kidney condition called Acute Tubulointerstitial Nephritis (TIN).


Q: Does Aciban interact with blood pressure medication?

Official drug labels list established interactions with specific medicines but do not typically provide a blanket statement covering all blood pressure medications. Although not consistently listed as a direct interaction, some scientific studies reviewed by regulatory bodies have explored a potential association between long-term use of PPIs and an increased risk of hypertension.


Q: What if Aciban does not seem to be working after a few weeks?

If a patient is using the non-prescription form of Aciban and no symptom relief is obtained after two weeks of continuous treatment, regulatory advice states that consultation with a doctor is indicated. The medicine is designed to achieve sustained suppression when used according to official guidelines.


Q: Can Aciban be taken with supplements like vitamins or herbal products?

Official regulatory information specifies that Aciban (Pantoprazole) can interfere with the absorption of certain micronutrients like Vitamin B-12 and Iron Salts. While the drug label doesn't list every possible interaction, the potential for reduced absorption exists for any supplement whose action is sensitive to stomach acid levels.


Q: Is Aciban available in different strengths?

Yes, Aciban (Pantoprazole) is manufactured and distributed in multiple delayed-release oral strengths. According to official regulatory records, it is most commonly available in 20 mg and 40 mg forms.


Q: Does Aciban interact with birth control pills?

Specific regulatory studies have examined the potential for interaction between Aciban (Pantoprazole) and hormonal contraceptives. Official product information indicates that Aciban has been shown to have no clinically relevant effect on the efficacy of birth control containing levonorgestrel and ethinylestradiol.


Q: Is Aciban a new drug, or has it been around for a while?

The active ingredient in Aciban, Pantoprazole, is not a new drug. Reference medicines containing this compound were first authorized in major international regulatory regions, such as the European Union, as far back as 1994.


Q: Why is Aciban only available by prescription?

Regulatory bodies often distinguish between prescription-only and non-prescription (OTC) forms of Pantoprazole. Prescription forms (typically higher doses like 40 mg) are generally intended for use in the long-term management and treatment of a wider range of severe gastrointestinal diseases. Lower-dose forms may sometimes be approved for short-term, over-the-counter use.


Q: What should I do if I get a rash while using Aciban?

A rash is a documented adverse reaction, and there are reports of severe skin reactions with this class of medicine. The product information states that discontinuation and further evaluation by a healthcare provider are advised upon the first sign of a severe cutaneous (skin-related) reaction or other signs of hypersensitivity.


Q: What is the risk of stopping Aciban suddenly?

While not a specific warning on some regulatory labels, studies reviewed by official bodies note that abrupt discontinuation of Proton Pump Inhibitors (PPIs) may lead to short-term rebound acid hypersecretion. This condition can cause a return of acid-related symptoms. To manage this potential return of symptoms, gradual tapering has been noted as a strategy used by some medical professionals.


Q: Are there any documented cases of overdose with Aciban?

Regulatory information addresses overdosage by reviewing clinical experience and animal studies involving high doses. In high-dose animal studies, signs observed included ataxia (loss of muscle control), hypoactivity, and lethargy. Specific human overdose case reports are not typically listed in the product labeling.


Q: Does Aciban affect blood sugar levels?

The official drug label does not list an effect on blood sugar (glucose) as a common or frequent adverse effect. However, some clinical studies have been conducted to investigate the possible impact of Pantoprazole on glycemic control in individuals with Type 2 Diabetes.

How should Aciban be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory agencies define specific conditions for storing and disposing of Aciban (Ranitidine) to maintain its chemical stability and safety.

Storage and Handling

Aciban must be stored in its original bottle with the desiccant included and kept tightly closed to protect it from moisture and high temperatures. If the tablets are reformulated, the medication must be discarded 90 days after the bottle is first opened, or by the bottle's expiration date, whichever occurs sooner. The product should be kept out of the sight and reach of children.

Disposal Protocol

Expired or unused Aciban should not be flushed down the toilet or poured down the sink. Instead, it must be disposed of in the household trash by mixing it with an unappealing substance, such as dirt or coffee grounds, and sealing the mixture in a plastic bag before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aciban found in:

A-Z Index: